abstract |
The invention relates to IP receptor antagonists selected from the group of compoundsnrepresented by formulan nwhereinn R 1 is a group represented by formula (A), (B) or (C):n nand other substituents as defined in the specification, and their pharmaceuticallynacceptable salts, crystal forms therof and pharmaceutical compositions containing them. |